# US 2018/0021401 A1 · Compositions and methods for treatment of intracellular damage and bacterial infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021401 A1
- Document ID: US20180021401A1
- Status: Published application
- Kind: A1
- Application number: 15/672,903
- Filed: 2017-08-09
- Published: 2018-01-25
- Earliest claimed: 2011-03-02
- Assignees: Bioincept, LLC
- Applicants: BioIncept, LLC
- Inventors: Eytan R. Barnea
- Web page: https://patentgrep.com/patent/US20180021401A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/217: {IFN-gamma}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.

## Claims

### Claim 1

A method of treating atherosclerosis comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1 further comprising administering a potassium channel inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the potassium channel inhibitor is a Kv1.3 inhibitor.

### Claim 4 (depends on 2)

The method of claim 2, wherein the potassium channel inhibitor is IFNγ.

### Claim 5 (depends on 1)

The method of claim 1, wherein atherosclerotic plaque is reduced.

### Claim 6 (depends on 5)

The method of claim 5, wherein atherosclerotic plaque is reduced in an aortic arch, an aortic root, or combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein monocyte proteins are reduced in an aortic arch, an aortic root, or combinations thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the monocyte proteins are selected from one or more of vascular cell adhesion molecules, monocyte chemotactic proteins, and clusters of differentiation.

### Claim 9 (depends on 8)

The method of claim 8, wherein the monocyte proteins are selected from one or more of VCAM-1, MCP-1, and CD68.

### Claim 10 (depends on 1)

The method of claim 1, wherein levels of lipids are reduced in an aortic arch, an aortic root, or combinations thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein levels of circulating lipids is not substantially affected.

### Claim 12 (depends on 1)

The method of claim 1, wherein cytokines are reduced in THP-1 cells, an aortic arch, an aortic root, or combinations thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cytokines are selected from one or more of interleukin 12, subunit beta (IL-12b) and interferon gamma (IFNγ).

### Claim 14 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5.0 mg/kg of the subject.

### Claim 15 (depends on 1)

The method of claim 1, wherein the number of foam cells are reduced in an aortic arch, an aortic root, or combinations thereof.

### Claim 16

A method of reducing atherosclerotic plaque and/or inhibiting atherosclerotic lesion development in a subject, comprising administering to the subject a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the PIF peptide is SEQ ID NO: 3 or a pharmaceutically acceptable salt thereof.

### Claim 18

A method of decreasing recruitment to and/or retention of monocytes within an atherosclerotic lesion in a subject, comprising administering to the subject a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the PIF peptide is SEQ ID NO: 3 or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 18)

The method of claim 18, wherein the atherosclerotic lesion is located in an aortic arch, an aortic root, or combinations thereof.
